Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SYNC-T
- Development stage
- Phase 2
- Lead developer
- Syncromune
- Modality
- MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intratumoral
01
Overview
**SYNC-T** is Syncromune's investigational, personalized in situ cancer-immunotherapy regimen for metastatic solid tumors. The therapy uses image-guided device-induced partial tumor cryolysis to release patient-specific tumor antigens and create an in situ multi-antigen vaccine, followed immediately by intratumoral administration of the fixed-dose multi-target biologic combination **SV-102**. SV-102 contains low-dose anti-PD-1 and anti-CTLA-4 monoclonal antibodies, a CD40 agonist monoclonal antibody, and a TLR9 agonist CpG oligodeoxynucleotide. The regimen is intended to synchronize tumor-antigen release, local immune activation, and checkpoint blockade to generate systemic antitumor T-cell responses while limiting systemic exposure. Syncromune is developing SYNC-T Therapy SV-102 in metastatic castration-resistant prostate cancer.
- Brand names
- SYNC-T SV-102
- Other names
- SYNC-T Therapy
02
Targets
CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)PDCD1 (Programmed cell death protein 1 receptor)TLR9 (Toll-like receptor 9)CD40 (Cluster of differentiation 40 receptor)
Beyond the preview
Go deeper on SYNC-T.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SYNC-T.